Pershing Square Capital Management, L.P. : Allergan, Inc. Derivative Securities Securities Litigation
On or around 07/07/2017 (Ongoing date of last review)
Filing Date: June 28, 2017
According to the Complaint, it is alleged that this action is based upon Defendants' illicit insider trading and frontrunning scheme that caused billions of dollars in damages to Plaintiff and other similarly situated investors (collectively, the "Class" or "Derivatives Class") who sold Allergan call options, purchased Allergan put options and/or sold Allergan equity forward contracts contemporaneously with Pershing's illegal purchase of Allergan common stock, Allergan call options and Allergan equity forward contracts during the Class Period.
Company & Securities Information
Defendant: Pershing Square Capital Management, L.P.
Industry: Investment Services
Headquarters: United States
Ticker Symbol: AGN
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Timber Hill LLC, et al. v. Pershing Square Capital Management, L.P., et al.